| Dr Davinder Kaur Chandhoke, MD | |
|
85-39 Wareham Place, Jamaica, NY 11432 | |
| (718) 558-2718 | |
| Not Available |
| Full Name | Dr Davinder Kaur Chandhoke |
|---|---|
| Gender | Female |
| Speciality | Pathology |
| Experience | 42 Years |
| Location | 85-39 Wareham Place, Jamaica, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639290760 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0101X | Pathology - Anatomic Pathology | 184566 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Barnabas Hospital | Bronx, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sbh Physicians Pc | 3072798941 | 159 |
News Archive
A research team led by scientists and doctors in Leicester and the Netherlands has shown that a urine test to measure whether patients are taking their medications will save the NHS money.
Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel's Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.
The unofficial "kickoff" to summer is only a few weeks away. While we hope everyone has fun this coming Memorial Day weekend, the nation's emergency physicians want everyone to stay safe and out of the ER.
Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemia (AML) blast, progenitor and even stem cells that are often resistant to standard chemotherapy treatment.
› Verified 4 days ago
| Entity Name | Brookdale Hospital Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720028772 PECOS PAC ID: 4284545799 Enrollment ID: O20031120000600 |
News Archive
A research team led by scientists and doctors in Leicester and the Netherlands has shown that a urine test to measure whether patients are taking their medications will save the NHS money.
Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel's Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.
The unofficial "kickoff" to summer is only a few weeks away. While we hope everyone has fun this coming Memorial Day weekend, the nation's emergency physicians want everyone to stay safe and out of the ER.
Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemia (AML) blast, progenitor and even stem cells that are often resistant to standard chemotherapy treatment.
› Verified 4 days ago
| Entity Name | Newyork-presbyterian-queens |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013960962 PECOS PAC ID: 7315839933 Enrollment ID: O20040329000273 |
News Archive
A research team led by scientists and doctors in Leicester and the Netherlands has shown that a urine test to measure whether patients are taking their medications will save the NHS money.
Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel's Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.
The unofficial "kickoff" to summer is only a few weeks away. While we hope everyone has fun this coming Memorial Day weekend, the nation's emergency physicians want everyone to stay safe and out of the ER.
Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemia (AML) blast, progenitor and even stem cells that are often resistant to standard chemotherapy treatment.
› Verified 4 days ago
| Entity Name | Sbh Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740595917 PECOS PAC ID: 3072798941 Enrollment ID: O20110420000217 |
News Archive
A research team led by scientists and doctors in Leicester and the Netherlands has shown that a urine test to measure whether patients are taking their medications will save the NHS money.
Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel's Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.
The unofficial "kickoff" to summer is only a few weeks away. While we hope everyone has fun this coming Memorial Day weekend, the nation's emergency physicians want everyone to stay safe and out of the ER.
Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemia (AML) blast, progenitor and even stem cells that are often resistant to standard chemotherapy treatment.
› Verified 4 days ago
| Entity Name | New York Queens Medicine And Surgery, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003114851 PECOS PAC ID: 4082883673 Enrollment ID: O20110817000163 |
News Archive
A research team led by scientists and doctors in Leicester and the Netherlands has shown that a urine test to measure whether patients are taking their medications will save the NHS money.
Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel's Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.
The unofficial "kickoff" to summer is only a few weeks away. While we hope everyone has fun this coming Memorial Day weekend, the nation's emergency physicians want everyone to stay safe and out of the ER.
Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemia (AML) blast, progenitor and even stem cells that are often resistant to standard chemotherapy treatment.
› Verified 4 days ago
| Entity Name | Kingsbrook Medical Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104112838 PECOS PAC ID: 8729252028 Enrollment ID: O20111123000332 |
News Archive
A research team led by scientists and doctors in Leicester and the Netherlands has shown that a urine test to measure whether patients are taking their medications will save the NHS money.
Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel's Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.
The unofficial "kickoff" to summer is only a few weeks away. While we hope everyone has fun this coming Memorial Day weekend, the nation's emergency physicians want everyone to stay safe and out of the ER.
Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemia (AML) blast, progenitor and even stem cells that are often resistant to standard chemotherapy treatment.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Davinder Kaur Chandhoke, MD 85-39 Wareham Place, Jamaica, NY 11432 Ph: (718) 558-2718 | Dr Davinder Kaur Chandhoke, MD 85-39 Wareham Place, Jamaica, NY 11432 Ph: (718) 558-2718 |
News Archive
A research team led by scientists and doctors in Leicester and the Netherlands has shown that a urine test to measure whether patients are taking their medications will save the NHS money.
Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus, today announces that the US Food and Drug Administration (FDA) has cleared Genticel's Investigational New Drug application to conduct in the US a phase 1 clinical study of GTL001 in patients infected with HPV 16 and/or 18, the two HPV types responsible for 70% of cervical cancer cases.
The unofficial "kickoff" to summer is only a few weeks away. While we hope everyone has fun this coming Memorial Day weekend, the nation's emergency physicians want everyone to stay safe and out of the ER.
Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemia (AML) blast, progenitor and even stem cells that are often resistant to standard chemotherapy treatment.
› Verified 4 days ago
Dr. Tai Park, Pathology Medicare: Not Enrolled in Medicare Practice Location: 8900 Van Wyck Expy, Jamaica, NY 11418 Phone: 718-206-6290 | |
Dr. Parul Anup Gheewala, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 15211 89th Ave, Jamaica, NY 11432 Phone: 516-741-5465 | |
Dr. Kristen Landi, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 160-15 82nd Drive, Jamaica, NY 11432 Phone: 718-557-8755 | |
Dr. Laurie Horowitz, Pathology Medicare: Accepting Medicare Assignments Practice Location: 8900 Van Wyck Expy, Jamaica, NY 11418 Phone: 718-206-6695 | |
Dr. Sicong Ren, M.D Pathology Medicare: Accepting Medicare Assignments Practice Location: 8900 Van Wyck Expy, Jamaica, NY 11418 Phone: 718-206-6695 | |
Dr. Kara I. Storck, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 160-15 82nd Drive, Jamaica, NY 11432 Phone: 718-557-8735 |